Text Size

Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

This study has been completed.
Sponsor:
Information provided by:
PharmaNeuroBoost N.V.
ClinicalTrials.gov Identifier:
NCT00672659
First received: May 2, 2008
Last updated: April 29, 2011
Last verified: April 2011
History of Changes
  Purpose

The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.

Secondary objectives are to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD:

  1. Will increase the rate of resolution of symptoms with citalopram 40 mg.
  2. Show the combined product to be safe and tolerable.

Patients are scheduled to receive study medication for eight weeks and a final follow-up check will be carried out 28 days after completing the study.

All patients will receive active citalopram from baseline and will be randomised to receive either active pipamperone or a placebo equivalent for eight weeks during which time they will attend for 6 study visits.


Condition Intervention Phase
Depression
 Drug: Citalopram + Pipamperone
Drug: Citalopram
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD)

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by PharmaNeuroBoost N.V.:

Primary Outcome Measures:
  • Change in Montgomery-Asberg Depression Rating Scale score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS [ Time Frame: At Weeks 1 and 2 ] [ Designated as safety issue: No ]

Enrollment: 165
Study Start Date: February 2008
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
 Drug: Citalopram + Pipamperone
Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
Placebo Comparator: 2
Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
 Drug: Citalopram
Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients
  • 18-65 years inclusive
  • Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode
  • Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0.
  • Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline
  • A non-psychotic state
  • Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication

Exclusion Criteria:

  • Premenopausal females not using adequate contraceptive measures
  • Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10
  • Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis
  • Significant physical illness which would interfere with trial assessments
  • Reduced hepatic function
  • Epilepsy
  • History of cardiac dysrhythmia
  • Alcohol intake above accepted UK ranges
  • Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers

  • Resistant depression defined as having failed to respond to

    • Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode
    • To an augmentation therapy with an atypical antipsychotic drug
  • Electroconvulsive therapy (ECT) for the current episode
  • Formal psychotherapy or alternative treatments for one week prior to or during the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00672659

Locations
United Kingdom
CPSResearch
Glasgow, Scotland, United Kingdom, G20 0XA
Sponsors and Collaborators
PharmaNeuroBoost N.V.
Investigators
Study Chair: Erik Buntinx, MD PharmaNeuroBoost N.V.
Study Director: Alan Wade, MG CPSResearch
Principal Investigator: Gordon Crawford, MD CPSResearch
  More Information

Additional Information:
Pubmed abstract  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Erik Buntinx, MD, PharmaNeuroBoost N.V.
ClinicalTrials.gov Identifier: NCT00672659     History of Changes
Other Study ID Numbers: PNB/CPS 02 2007
Study First Received: May 2, 2008
Last Updated: April 29, 2011
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by PharmaNeuroBoost N.V.:
Lost of interest, Depressed Mood

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Citalopram
Dexetimide
Pipamperone
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
 Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Antipsychotic Agents

ClinicalTrials.gov processed this record on May 22, 2013